dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleMIT Technology Review

The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid Date: 2026-09-16 12:10 Source: https://www.technologyreview.com/2026/09/16/1144205/the-download-ai-trillion-dollar-build-openai-biological-data/ <p><em>This is today’s edition of </em><a href="https://form…
Opening lines of the source · MIT Technology Review · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Competition will push AI labs toward safety.

    60% confidence
  • Americans trust Silicon Valley even less than Washington, reflecting a lack of faith that tech companies will act in the public interest.

    60% confidence
  • Its AI agents have sent 1.6 million spam messages.

    60% confidence
  • New AI safety laws are unnecessary.

    60% confidence
  • Data obtained by bidding at failed biotech companies' bankruptcy proceedings—regulatory filings, manufacturing strategies, safety data—could create a 'biotech's lost archive' to supercharge medical AI systems.

    60% confidence
  • The rejuvenation treatment blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism, and restores health and youth to multiple tissues.

    60% confidence
  • AI companies will need to achieve an extraordinary increase in productivity just to break even by 2030 given planned hyperscaler spending through 2027.

    60% confidence
  • Granting AI companies antitrust waivers is suspect and should not be done.

    60% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid: Source | Via News | fr.via.news